Dr Reddy’s licenses Aegis’ drug delivery tech
Dr Reddy’s Laboratories is combining some of its products with Aegis Therapeutics’ Intravail drug delivery technology after the companies entered into a partnership.
The deal allows Dr Reddy’s to use Intravail with certain currently marketed products with annual worldwide sales of more than $1bn (€708m). Details of which products are included in the deal have not been disclosed.
Dr Reddy’s believes the products in development will satisfy a significant unmet need in the market. Clinical trials using the technology have been completed but no development timeline has been revealed.
Products developed under the exclusive license agreement will be manufactured and marketed by Dr Reddy’s.
